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The success of pregnancy is contingent on the maternal immune system recognizing 
and accommodating a growing semi-allogeneic fetus. Specialized subsets of lympho-
cytes capable of negative regulation are fundamental in this process, and include the 
regulatory T cells (Tregs) and potentially, regulatory B cells (Bregs). Most of our current 
understanding of the immune regulatory role of Bregs comes from studies in the fields 
of autoimmunity, transplantation tolerance, and cancer biology. Bregs control autoim-
mune diseases and can elicit graft tolerance by inhibiting the differentiation of effector T 
cells and dendritic cells (DCs), and activating Tregs. Furthermore, in cancer, Bregs are 
hijacked by neoplastic cells to promote tumorigenesis. Pregnancy therefore represents 
a condition that reconciles these fields—mechanisms must be in place to ensure mater-
nal immunological tolerance throughout gravidity to allow the semi-allogeneic fetus to 
grow within. Thus, the mechanisms underlying Breg activities in autoimmune diseases, 
transplantation tolerance, and cancer may take place during pregnancy as well. In this 
review, we discuss the potential role of Bregs as guardians of pregnancy and propose an 
endocrine-modulated feedback loop highlighting the Breg–Treg–tolerogenic DC interface 
essential for the induction of maternal immune tolerance.
Keywords: regulatory B cells, regulatory T cells, autoimmunity, cancer, pregnancy, tolerance, estrogen, 
progesterone
iNTRODUCTiON
Pregnancy is a remarkable biological process wherein the mother carries an offspring that is 
semi-allogenic, that is, half of its genome is derived from the foreign paternal parent. It imposes 
significant physiological stress, requiring the mother’s body to undergo immense functional changes. 
Pregnancy in mammals represents a unique compromise in the context of immunity—the maternal 
immune system must accommodate the semi-allogenic fetus by dampening its immune responses 
to maintain a state of immunological tolerance throughout gravidity, while retaining the capacity 
to identify pathogens and destroy them with appropriate control of resultant inflammation. This 
dichotomy necessarily requires a fine and highly regulated balance between immune tolerance and 
immune activation.
In pregnancy, the immune profiles of dendritic cells (DCs), natural killer cells, macrophages, 
and T cells are by necessity modified (1–4). Recently, it has been shown that the B cell profile is also 
modified in response to the immunological needs of the mother during pregnancy (5). The role 
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of B cells in pregnancy holds much interest, especially in light 
of the recent identification of a B cell subset capable of negative 
regulation, that is, can suppress immune inflammation. Due to 
their unique role amongst the B cell types, this subset is aptly 
designated as ‘regulatory B cells’ or ‘Bregs.’
Regulatory B cells are being extensively studied in three major 
fields: autoimmunity, transplantation tolerance, and cancer. 
Seemingly different, conditions in these fields are in fact outcomes 
of immune dysfunction. Whereas autoimmune diseases reflect an 
inadequate ability to control an overactive immune response to 
self, development of cancer results from the enthusiastic suppres-
sion of the immune system thus allowing a mutated self to survive 
and proliferate. The role of Bregs as negative regulators of the 
immune system varies in these different contexts. As mediators 
of immune suppression, they have been implicated in the cessa-
tion of autoimmune diseases and graft tolerance as the expansion 
of the Breg population is highly correlated with amelioration of 
the disease and maintenance of tolerance (6). On the other hand, 
Bregs have been tagged as pro-tumorigenic due to their capacity 
to inhibit the action of effector immune cells whose purpose is to 
identify and eliminate cancer cells, hence providing a favorable 
environment for the tumor to grow (7, 8).
As pregnancy requires selective immunological tolerance, this 
condition may be viewed as a reconciliation of the two extreme 
paradigms. The mechanisms that inhibit immune flares or chronic 
inflammation in autoimmune diseases and transplantation may 
be at play in the induction of maternal immune tolerance dur-
ing pregnancy. Similarly, the pro-tumorigenic mechanisms that 
allow cancer development to take place may also be responsible 
for allowing the growth and development of a semi-allogeneic 
fetus in the mother’s womb. In this review, we investigate the 
possible mechanisms by which Bregs confer protection to the 
semi-allogeneic fetus during pregnancy by assessing their role 
in autoimmune diseases, graft tolerance, and cancer. We also 
examine how the maternal endocrine system sets the stage for 
pregnancy, particularly how it endeavors to create an environ-
ment conducive for the expansion of Bregs.
ReGULATORY B CeLLS
B cells are best known to organize immune responses by produc-
tion of antibodies. Representing the humoral arm of adaptive 
immunity, they are the primary facilitators of antigen-specific 
immune responses via antibody production and differentiation 
into memory cells that provide long-lasting immunity. However, 
reports over the past 40 years indicate that not all B cells function 
for that purpose. The earliest studies (1974) found that B cells 
could suppress delayed-type hypersensitivity reactions in guinea 
pigs, implying an inhibitory effect of B cells on T cell function 
(9, 10). Further evidence of this B cell regulatory phenotype 
eventuated more than two decades later, with the observation in 
a murine autoimmune model that inflammation was exacerbated 
in the absence of B cells (11). While this suggested that B cells 
may play a down-modulating role in the inflammatory response, 
it was only in 2000 that Mizoguchi et al. formally described and 
reported a subset of B cells that inhibited, rather than promoted, 
the inflammatory response in a mouse model of inflammatory 
bowel disease (12). This peculiarly suppressive B cell subset was 
classified as ‘regulatory B cells’ or ‘Bregs.’ Since then, defective 
Breg function or deficiency in Breg levels have been implicated 
in conditions involving uncontrolled pro-inflammatory immune 
responses; most extensively in autoimmune diseases and renal 
transplantation cases (13–16).
Breg Phenotypic identification
Defining a specific Breg phenotype has proven to be a difficult as 
multiple B cell “subsets” have been reported to function as nega-
tive regulators of the immune response. While there is no unifying 
characteristics with respect to cell surface activation and lineage 
markers as of yet, initial reports indicated that the regulative 
properties of these unique B cells were attributed exclusively to 
the production of the anti-inflammatory cytokine interleukin-10 
(IL-10) (13, 17, 18). However, more recent studies have revealed 
B cell subsets with IL-10-independent regulatory functions, indi-
cating that some Bregs employ a multi-mechanistic, and possibly 
cooperative, approach for regulating immune responses. Given 
the lack of a unified approach and as IL-10 production is the most 
reported mechanism of suppressive action; IL-10 production 
remains the defining feature of Bregs.
Different B-cell subsets that have been attributed with regula-
tory function in mice include the transitional 2 marginal-zone 
precursor (T2-MZP) cells, CD5+CD1dhiIL-10+ B (B10) cells, 
follicular (FO) B cells, marginal-zone (MZ) B cells, CD5+B-1a 
cells, CD5+CD178+ killer B cells, GIFT-15 B cells, plasma cells, 
plasmablasts, TIM-1+ B cells, and PD-L1hi B cells (19, 20). In 
humans, immature B cells, IL-10+ B cells (B10), GrB+ B cells, Br1 
cells, and plasmablasts are reported to play immunosuppressive 
roles (19). Despite the diversity in phenotype, most B cell subsets 
that carry out negative regulation produce anti-inflammatory 
cytokines, with the majority of the cell surface marker-defined 
subsets enriched with IL-10-producing cells. In mice, the sup-
pressive IL-10-producing Bregs, also known as B10 cells are char-
acterized by the CD1dhiCD5+ phenotype (21). Among the splenic 
B10 cells, both marginal-zone B (MZ B) cells and T2-MZP B cells 
have been shown to have a protective effect in mouse models of 
lupus and autoimmune arthritis due to their IL-10 competency 
(22, 23). The peritoneal cavity contains B-1a cells that are also a 
major source of IL-10 (24). In humans, CD19+CD24hiCD38hi B 
cells isolated from human peripheral blood are classified as Bregs 
due to their ability to suppress inflammation by a combination of 
IL-10 production and CD80 and CD86 costimulation (25), while 
the IL-10-competent CD24hiCD27+ B cells are proposed as the 
Breg subset analogous to the mouse regulatory B10 cells (26). The 
heterogeneity of these subsets suggests that Bregs are not derived 
from one specific lineage; rather they may acquire their regula-
tory ability through exposure to environmental stimuli.
Since surface markers identifying these subsets are varied, 
there are currently ongoing attempts to identify a unique global 
indicator for Bregs, analogous to the transcription factor FOXP3, 
a defining feature of regulatory T cells (Tregs). Evidence suggests 
that the T cell immunoglobulin and mucin domain 1 (TIM-1) 
may be an inclusive marker for Bregs as it identifies about 70% of 
all IL-10+ B cells in all subsets mentioned (27). However, CD9 has 
also been reported as a marker for murine IL-10-competent Bregs 
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by virtue of transcriptomic analysis which strongly associated its 
expression with Breg biogenesis and function (28). In principle, 
identification of a unique marker signifying a direct regulatory 
function in B cells would reduce the reliance on functional assays 
and increase our understanding of the role that Bregs may play 
in different diseases and allow exploration of therapeutic options. 
To date, elucidating the Breg phenotype and underlying ontology 
continues to be an active research endeavor.
Bregs’ Suppression Mechanisms
Since formal recognition, Bregs have been described mainly in the 
context of autoimmunity, transplantation tolerance, and cancer. 
The best studied mechanism for negative regulation of Bregs is 
their capacity to produce anti-inflammatory cytokines, especially 
IL-10. The principal function of IL-10 is to repress excessive 
inflammation and maintain homeostasis through numerous 
mechanisms, which includes hampering antigen presentation 
and expression of costimulatory molecules CD80, CD86, and 
MHC class II by macrophages and DCs, as well as limiting the 
activation of and cytokine release by T cells in immune responses 
and promoting the differentiation of Tregs (29).
While IL-10 production remains the hallmark of Breg’s nega-
tive regulatory function, other independent suppressive mecha-
nisms have come to light in recent years and include transforming 
growth factor beta (TGF-β), IL-35, and IL-17. Production of 
TGF-β by B cells leads to promotion of Treg development in 
diabetes, transplant tolerance, allergic diseases, and colitis (30). 
Moreover, about 60% of IL-10-producing B cells in mice also 
express IL-35, a cytokine identified as a key player in the recovery 
phase of experimental autoimmune encephalomyelitis (EAE), 
and necessary for improved resistance to Salmonella infection 
(31). Secretion of IL-17 by activated B cells has been reported 
to occur upon contact with parasite-derived trans-sialidase, 
a feature shown to be critical in the control and resolution of 
infection (32). This result emphasizes the importance of Breg 
function in a disease that has a high potential to develop into 
chronic inflammation.
Various surface molecules on B cells have also been identified 
as the main instigators of negative regulation upon cognate inter-
action with pro-inflammatory cells. Among the most studied are 
programmed death receptor ligand 1 (PD-L1), granzyme B, and 
Fas ligand (FasL). Upregulated PD-L1 expression on B cells is 
critical in down-modulating T cell activity. In EAE, adoptive 
transfer studies demonstrate that PD-L1+ B cells confer protec-
tion and reduce disease severity via restriction of helper T (Th) 
cells inflammatory role and induction of Treg activity (33–35). 
Furthermore, PD-L1+ B cells have been shown to regulate cyto-
toxic T cells in both Salmonella infection and prostate cancer 
(36, 37), with high expression shown to directly suppress the FO 
Th response and differentiation via attenuation of downstream 
signaling pathways concomitant to programmed death recep-
tor 1 (PD-1) ligation (38). Similarly, B cells expressing FasL 
were found to be critical in preventing graft rejection in mice 
and modulating the induction of autoimmune disease through 
a myriad of mechanisms including promotion of apoptosis of 
autoreactive T cells and the generation of Tregs (39, 40). Lastly, 
IL-21-induced granzyme B expression in B cells was shown to 
impart a regulatory function against effector T cells in the tumor 
microenvironment (41).
Breg Detection and expansion
Due to the inconsistencies in specific surface markers used to 
classify Breg subsets, the most common approach for Breg iden-
tification remains a combination of surface marker staining and 
intracellular IL-10 staining. In mice, isolated Bregs do not readily 
produce IL-10 ex vivo, therefore to identify this specific subset of B 
cells, cells are subjected to acute B cell stimulation—5 h of culture 
with a cocktail of lipopolysaccharide (LPS), phorbol 12-myristate 
13-acetate, and ionomycin to enhance the translation of cytokine 
genes, and thus detectable IL-10 production (42). In the spleen 
and other lymphoid tissues, Breg progenitor cells have also been 
identified (43). These are defined as B cells that do not express 
IL-10 following the short-term stimulation but may be induced to 
Breg maturation and IL-10 competency by culture with agonistic 
CD40 monoclonal antibody for 48 h. This technique has proven 
beneficial for expanding this rare subset for subsequent in vivo 
applications such as adoptive transfer experiments. Together, 
active and progenitor Bregs account for 3–8% of basal B cell 
levels in the murine spleen, of which 1–3% are IL-10-competent 
Bregs. Lower percentages are found in the blood, lymph nodes, 
intestinal tissues, Peyer’s patches, and the central nervous system 
(21, 44, 45). In humans, IL-10-producing B cells isolated from the 
peripheral blood are found to express increased levels of CD19, 
IgD, CD27, CD48, and/or CD148 at varying proportions and 
phenotypic combinations. IL-10-competent Bregs have also been 
identified in peripheral tissues such as spleen, tonsils, and umbili-
cal cord blood at less than 1% of the total B cell population (26).
Bregs iN AUTOiMMUNiTY
In the last decade, numerous studies have been conducted to 
determine the operating mechanisms that impart Breg-mediated 
suppressive function. The majority of what is currently known 
stems from the multitude of studies focusing on autoimmune 
diseases where it has been demonstrated that Bregs interact and 
regulate the function of T cells, DCs, monocytes, macrophages, 
and natural killer cells.
The regulatory role of B cells in EAE, a mouse model for multi-
ple sclerosis (MS), was first apparent when exacerbation of disease 
was observed in B cell-deficient B10.PLμMT mice (11). The cur-
rent model posits that Bregs regulate EAE severity through IL-10 
production and expression of costimulatory molecules CD40, 
CD80, and CD86, thus limiting the type 1 cytokine response via 
cross talk between B cells and T cells, and recruitment of FOXP3+ 
Tregs into the central nervous system (6, 14). B cells expressing 
toll-like receptor (TLR)-2 and TLR-4 also suppressed inflamma-
tory T cell responses (Th1 and Th17) and stimulated the recovery 
phase of EAE (46). Other mechanisms such as the presence of 
glucocorticoid-induced TNF ligand and elevated levels of B and T 
lymphocyte attenuator on B cells also play a role in inducing and 
maintaining the Treg pool in the central nervous system during 
EAE, a process which ultimately facilitates the protection against or 
amelioration of the disease (47, 48). Interestingly, recent evidence 
indicates that Bregs can also directly access the central nervous 
4Guzman-Genuino and Diener Regulatory B Cells in Pregnancy
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 172
system (CNS). Bone marrow cells transiently stimulated with the 
TLR-9 agonist CpG generate proB (CpG-proB) cells, which upon 
transfer to recipient mice at the onset of EAE symptoms differen-
tiate into mature B cells with regulatory function. Some of these 
mature B cells home to the inflamed CNS for local production of 
IL-10 thus instigating a switch of the host cytokine profile from 
inflammatory to immunoregulatory, while others enter reactive 
lymph nodes and restrain encephalitogenic T cells via CCL19 
expression. Together these functions cooperatively enhanced 
amelioration of active EAE (49). Evidence of the regulatory 
function of B cells in human disease is also accumulating, with B 
cells from MS patients observed to have diminished capacity for 
IL-10 production on activation as opposed to healthy controls. 
This suggests that dysregulation of this pathway contributes to 
MS pathogenesis (50–52).
Type 1 diabetes (T1D) is characterized by the autoimmune-
mediated destruction of pancreatic β cells. Circulating 
CD19+CD27−CD24hiCD38hi Bregs have been found to decrease 
with age and as such are hypothesized to be a major contributing 
factor to the prevalence of T1D in older age groups (53). Patients 
with T1D also exhibit the lowest frequency of B10 cells compared 
with patients with type 2 diabetes, latent autoimmune diabetes 
in adults, and healthy controls (54). These results highlight the 
importance of B cells in the immunopathogenesis of autoim-
mune diabetes and suggest that antigen-activated B10 cells may 
have a role to play in inhibiting autoreactive T cell responses to 
islet-specific antigen in healthy individuals, as the absence of this 
population leads to hyperglycemia in T1D patients. In non-obese 
diabetic (NOD) mice, adoptive transfer of CD1dhiCD5+IL-10+ 
Bregs prevented T1D development. Further, the addition of 
tolerogenic DCs to the transferred therapeutic mix reversed the 
onset of T1D by augmenting the frequency of IL-10+ Bregs (55). 
In the same manner, adoptive transfer of CpG-proB cells, either 
directly or indirectly after maturation into mature Bregs, protected 
against the pathogenesis of T1D in NOD mice via suppression of 
IL-21 and induction of apoptosis in effector T cell populations, 
including specific diabetogenic T cells (56). The DC- and CpG-
mediated suppression of T1D through Breg activity reiterates the 
notion that B cells have an intrinsic suppressive potential, which 
is only activated when the environmental cues are appropriate.
In systemic lupus erythematosus (SLE), Bregs are emerging as 
vital players during disease initiation. Adoptive transfer of splenic 
CD5+CD1dhi Bregs from wild-type mice extended the survival 
period of CD19−/− mice in this spontaneous lupus model (57). In 
humans, SLE patients exhibited similar frequencies of circulating 
CD24hiCD38hi B cells but had significantly lower IL-10+ percent-
ages compared to normal healthy controls (58). Further, there is 
evidence of functional impairment in Bregs from SLE patients. 
Isolated Bregs were unresponsive to CD40 ligation and exhib-
ited lower IL-10 production compared to Bregs obtained from 
normal patients, which resulted in inadequate suppression of T 
cell activation and proliferation (59). Compromised cross talk 
between IL-10-producing CD24+CD38hi Bregs and interferon 
alpha-producing plasmacytoid dendritic cells has also been 
documented as a key contributor to the pathogenesis of SLE (60).
Studies of rheumatoid arthritis (RA) suggest that Bregs are 
responsible for the primary induction of Tregs. Specifically, IL-10 
from B cells aids in the establishment of the Treg to inflammatory 
Th1 and Th17 cell ratio as seen in chimeric (IL-10−/− B cell) mice 
which exhibit a significant decrease in FOXP3 expressing CD4+ T 
cells; the low number of Tregs occurred in parallel with an increase 
in Th1 and Th17 cell populations in the draining lymph nodes of 
the inflamed joints (61). Furthermore, the adoptive transfer of 
Bregs into these chimeric mice restored the Treg population to 
normal levels and decreased inflammation by inhibiting Th1 and 
Th17 differentiation, thus decreasing IFNγ and IL-17 cytokine 
levels, and reinstating a balanced Th1/Th2 response (62). This 
notion of Bregs influencing T cell plasticity was similarly dem-
onstrated by injection of exogenous B10 cells which effectively 
suppressed the development of arthritis by suppressing Th17 
cell generation (63). Clinical studies report decreased frequency 
of CD24hiCD38hi Bregs in RA patients compared to unaffected 
individuals; it was shown that normal levels of Bregs effectively 
inhibited CD4+CD25− T cell differentiation into Th1 and Th17 
cells and promoted the differentiation of T cells into Tregs via 
IL-10 production (64). Moreover, it has been demonstrated that 
many RA patients achieve remission during pregnancy, presum-
ably due to a shift in T cell function from a Th1 to a Th2 pheno-
type, but relapse postpartum, a phenomenon possibly correlated 
to the increase of Breg levels during pregnancy and consequent 
decrease upon parturition (65–67).
The regulatory function of human B cells in autoimmune 
diseases is realized in case studies where complete B cell depletion 
therapy with rituximab (anti-CD20 monoclonal antibody) has 
resulted in aggravation of the disease or onset of new immune-
mediated pathologies. For instance, a patient with intractable 
ulcerative colitis experienced severe clinical aggravation of disease 
upon treatment with rituximab, a result ascribed to the depletion 
of both the intestinal and systemic suppressive B cell population 
(68). Similarly, rituximab was an effective treatment in a patient 
with Graves’ disease; however, development of ulcerative colitis 
and arthritis was observed shortly thereafter. Again, the depletion 
of colonic B cells was implicated, with symptoms alleviated upon 
repopulation (69).
Therefore, in autoimmune disease, the suppressive role of 
Bregs in the framework of T cell function occurs at two levels: (1) 
control of T cell plasticity by invoking the production of Tregs, 
inhibiting activation of naïve T cells, and suppressing Th differen-
tiation; and (2) manipulation of the production of proinflamma-
tory and anti-inflammatory cytokines and their balance thereof.
Bregs iN TRANSPLANTATiON 
TOLeRANCe
Graft tolerance has been best studied in liver and kidney trans-
plantations. Postoperative care involves continuous treatment 
with immunosuppressive drugs to prevent the immune response 
to the alloantigen, which may lead to organ rejection. Some 
recipients require immunosuppression medication for their 
entire lifetime; however there are reports of operationally tolerant 
recipients maintaining graft function despite immunosuppressive 
drug withdrawal (70). The containment of the inflammatory 
response that typically ensues without immunosuppressive drugs 
5Guzman-Genuino and Diener Regulatory B Cells in Pregnancy
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 172
points to the valuable function of regulatory immune cells—the 
Tregs which have an established role in graft tolerance, and the 
Bregs, whose role in transplantation has recently emerged.
Initial reports implicating a role for B cells as facilitators of 
graft tolerance resulted from studies investigating the effect of 
CD40 blockade on resting B cells. Permanent survival of mouse 
pancreatic islet allografts was demonstrated upon pretreatment 
with allogeneic non-T cell small lymphocytes (elutriated from 
spleen cell suspensions) plus blocking antibody to CD40L 
(71). Moreover, pretreatment of resting B cells with anti-CD40 
monoclonal antibody prolonged fully allogeneic mouse cardiac 
allografts and augmented the hyporesponsiveness to MHC 
molecules in vivo (72), suggesting a dominant role of the CD40/
CD40L pathway in tolerance induction. The mechanism by 
which anti-CD40 antibodies can elicit a tolerogenic response was 
elucidated a decade later when it was demonstrated that CD40 
ligation resulted in the differentiation of IL-10+ transitional-2 
(T2) Bregs, the rescue of B cells, and transitional B cell subsets 
from apoptosis, as well as prevention of differentiation into 
mature FO B cells. Specifically, anti-CD40 Ab administration 
induced the differentiation of T2 and MZ B cells and expanded 
the population of IL-10+ Bregs in vitro and in vivo, resulting in 
significantly improved renal disease and controlled progression 
of lupus in mice (73). This was also reflected in tolerant kidney 
and cord blood transplant patients where increased CD40 liga-
tion potentiated IL-10 production by naïve and transitional B 
cells (74–76).
In a rat model of kidney allografts, intravenous injection of 
bulk donor B cells to the recipient at the time of transplantation 
was by itself proven to be effective in inducing long-term accept-
ance (more than 300 days) of the graft. This was a significantly 
longer time period than when donor T cells were administered 
17  days after transplantation (77). Studies of islet  allografts in 
mice identified TIM-1 as an inclusive marker for IL-10 and IL-4 
expressing Bregs in all major B cell subpopulations including the 
transitional, MZ, FO, and CD5+CD1dhi cells. More importantly, 
ligation by anti-TIM-1 induced the regulatory function of these 
B cells constitutively expressing TIM-1 via IL-10 production. 
Adoptive transfer of TIM-1+ B cells from untreated BALB/c allo-
graft recipients into chemically diabetic B cell-deficient allograft 
recipients prolonged graft survival by activation of transferred 
IL-10-producing TIM-1+ B cells and augmented the frequency 
of FOXP3+ Tregs (27). Moreover, the mucin domain of TIM-1 
has been identified as being primarily responsible for Breg induc-
tion and maintenance in prolonged allograft survival (78). Aside 
from TIM-1+ Bregs, tolerance in a mouse model of MHC class I 
mismatched skin transplantation was associated with a transient 
expansion in T2 B cells in mice tolerized by donor splenocyte 
transfusion and ligation with CD40L. These tolerized B cells were 
characterized by expression of downregulated levels of CD86 and 
upregulated levels of TIM-1, and prolonged skin allograft survival 
in vivo, as well as suppressed T cell activation in vitro. Moreover, 
it was seen in this study that tolerized B cells and graft-specific 
Tregs worked synergistically in prolonging graft survival, albeit in 
an IL-10-independent fashion (79). Similarly, the adoptive trans-
fer of TGF-β-producing Bregs induced the expression of FOXP3 
in CD4+CD25− T cells, thus activating and expanding the Treg 
population which contributed to protracted graft survival (80). 
These reports reinforce the multi-mechanistic mode of suppres-
sion by Bregs in that through IL-10, TGF-β, CD86 costimulation, 
and other surface molecules, antigen-specific tolerized B cells no 
longer stimulate allospecific T cell activation, but instead support 
the induction of Treg function to enact a tolerogenic response.
In humans, research has also indicated a critical role for B 
cells in regulating alloimmunity. For operationally tolerant renal 
transplant recipients, renal allograft tolerance was strongly asso-
ciated with a B cell signature consisting of an increased expression 
of multiple B cell differentiation and activation genes over that 
observed in non-tolerant patients receiving immunosuppression 
and non-transplanted controls. The three genes identified as reli-
able predictors of operational tolerance—IGKV4-1, IGLL1, and 
IGKV1D-13—are genes that are upregulated during transition 
from pre-B to mature B cells and during class switching post-
antigen stimulation, suggesting that transitioning B cells may 
be highly involved in tolerance induction and/or maintenance 
(15). Moreover, operationally tolerant patients displayed higher 
transitional (CD24hiCD38hi) and naïve B cell frequencies, lower 
numbers of memory B cells, and an enriched IL-10+ B cell 
population—all phenotypes that were strongly associated with 
reduced allograft rejection rates (81–84). Together these recent 
findings suggest assigning a prospective biomarker status on 
transitional B cells. Additionally, operationally tolerant patients 
retain the capacity to activate the CD40 pathway essential to Breg 
activation (16), and although IL-10-producing Bregs are higher 
in these patients, other mechanisms such as granzyme B+ and 
TGF-β production may also account for the inhibitory effect on 
T cells essential to maintaining transplantation tolerance (80, 85).
Bregs iN CANCeR
Oncogenesis is primarily a battle between the immune system 
and the cancer stem cells. Tumor development and progression 
is dependent on the lenience of the microenvironment, to which 
leukocytes play a critical role. Both anti-tumorigenic and pro-
tumorigenic immune mechanisms transpire in the early stages 
of cancer development, with the net effect dictating whether 
the tumor develops or not (86). In particular, the induction of 
immune tolerance within the tumor environment has been 
shown to curtail immune-enhancing anti-tumorigenic efforts 
and encourage tumor progression and subsequent metastases. 
Immunosuppressive cells such as Bregs and Tregs have been 
implicated in facilitating immune tolerance, and ultimately, 
cancer escape.
For instance, tumor growth is contingent on the immune 
profile within the local microenvironment. Strong infiltration 
of antitumor CD8+ T cells and natural killer cells and decreased 
levels of regulatory B and T cells and myeloid-derived suppressor 
cells (MDSCs) all result in tumor destruction, whereas reversed 
proportions support tumor growth. In the tumor-draining 
lymph nodes, increased accumulation of B and T cells resulted in 
lymphangiogenesis and increased lymph flow (87), which con-
tributed to and accelerated the rate of metastasis (88). Moreover, 
B cell accumulation in lymph nodes of preneoplastic Eμ-c-myc 
mice was positively correlated with expansion of the lymphatic 
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sinuses and enhanced tumor growth, as opposed to preneoplastic 
B cell-deficient μMT mice which did not undergo lymphangi-
ogenesis and exhibited minimal tumor growth (89). However, 
tumor growth was accelerated in the B cell-deficient μMT mice 
upon adoptive transfer of naïve T2-MZP cells, highlighting the 
role of transitional and suppressive B cells in cancer escape. 
Furthermore, B cells bearing downregulated MHC class II and 
CD86 expression and upregulated Ly6A/E, PD-L1, and CD39 
selectively accumulated in the draining lymph nodes of mice with 
HPV-related cancer. The presence of PD-L1 and CD39 on the 
B cell surface confers regulative properties via direct inhibition 
of T cell function upon cognate interaction. The depletion of B 
cells in this model resulted in a robust Th1 cytokine response 
and decline in recruitment of Tregs, which was accompanied by 
a strong infiltration into the tumor of CD8+ T cells and ultimately 
tumor rejection (90). Interestingly, although primary colorectal 
tumors contain a significant memory and plasma B cell infiltrate 
suggestive of an active antitumor response, CD24hiCD38hi Bregs 
were significantly increased in metastatic tissue indicating a shift 
toward active immunosuppression in the local microenvironment 
(91). Thus the current literature suggests that B cell infiltration 
and accumulation in the tumor site and draining lymph nodes 
establishes an immunosuppressive microenvironment that leads 
to inhibition of antitumor immune responses and expansion of 
the critical lymphatic network, thereby facilitating tumor growth 
and metastasis.
Investigations into the specific role of Bregs in cancer have 
recently increased following the discovery of a unique B cell sub-
set termed tumor-evoked Bregs (tBregs) in Balb/c mice harboring 
4T1 carcinoma cells (8). In this model it was shown that cancer-
eradicating B cells were ‘hijacked’ by resident cancer cells within the 
tumor microenvironment and converted into immunosuppres-
sive Bregs. These tBregs do not conform to any of the established 
Breg phenotypes; instead they resemble activated mature B2 cells 
(CD19+CD25hiCD69hi and B7-H1hiCD81hiCD86hiCD62LloIgMint). 
Incubation of non-regulatory CD4+ T cells with tBregs bearing 
high expression levels of CD40, CD80, CD86, MHC class I and II 
molecules, and TGF-β production capacity led to the significant 
generation of CD4+CD25+FOXP3+ Tregs which in turn inhibited 
CD8+ T cell proliferation—thereby facilitating breast cancer 
escape and metastasis (8). More recently, it has been demonstrated 
that B cells infiltrating the mammary tumor bed are ‘educated’ 
through cognate interactions with resident tumor cells. These 
tumor-infiltrating B cells acquired PD-L1 expression and TGF-β 
competency which contributed to an immunosuppressive phe-
notype characterized by an enhanced inhibitory capacity against 
CD4+CD25− T cells, CD8+ T cells, and CD49b+NK cells, as well as 
promotion of Treg expansion (92). Therefore, infiltrating B cells 
subverted into Bregs by the tumor microenvironment facilitates 
the necessary critical changes in the local immune profile to sup-
port a pro-tumorigenic outcome.
In humans, studies reveal that a higher frequency of Bregs 
is indicative of enhanced tumor aggressiveness and poorer 
prognosis. For instance, hepatocellular carcinoma patients 
harbor significantly more peripheral Bregs compared to healthy 
controls (93); malignancy in non-small cell lung cancer is associ-
ated with an increased frequency of IL-10-producing Bregs, 
CD4+CD25+/highCD127low/− Tregs, and MDSCs (94); patients with 
tongue squamous cell carcinoma, gastric cancer, and colorectal 
cancer also exhibit a higher frequency of Bregs within the tumor 
itself compared to unaffected neighboring tissues, with numbers 
positively correlated with an increased frequency of Tregs (91, 95, 
96). Moreover, in vitro studies of lung cancer cells demonstrated 
their direct capacity to upregulate Treg and Breg phenotypes in 
lymphocyte cocultures (94). As for the mechanism, IL-10 and 
TGF-β competency appear to be the primary facilitators of sup-
pression. For example, peripheral blood CD19+CD24hiCD38hi 
Bregs isolated from gastric cancer patients converted CD4+CD25− 
effector T cells into CD4+FOXP3+ Tregs via expression of TGF-β 
(95). Moreover, IL-10 facilitates cross talk between CD19+IL-10+ 
Bregs and CD4+CD25− T cells in tongue squamous cell car-
cinoma patients, resulting in the conversion of these resting T 
cells into Tregs (96). Likewise, IL-10 has been shown to induce 
the expansion of Tregs in peripheral lymphoid organs in gastric 
cancer patients (95).
Bregs AND FeMALe SeX HORMONeS
The two major sex hormones involved in pregnancy are estrogen 
and progesterone, with each hormone playing a central role at 
different time points during gravidity. Progesterone promotes 
endometrial decidualization for the implantation of the embryo 
and maintains uterine relaxation throughout pregnancy (97). 
Estrogen on the other hand, plays a central role in angiogenesis 
which is needed for placentation and sustenance of the fetus 
(98). High estrogen levels and the withdrawal of progesterone 
promote the onset of labor, and ultimately, human parturition. 
Female sex hormones were found to have a significant influence 
on inflammatory responses when women with autoimmune 
conditions were reported to experience a change in their disease 
activity upon pregnancy. For instance, women that acquired SLE 
during pregnancy generally experienced a more severe affliction 
compared to non-pregnant patients (99, 100). Existing RA is 
often ameliorated by the surge of immunoinhibitory estrogen 
during pregnancy, which relapses postpartum upon an increase 
in the immunostimulatory hormone prolactin (101, 102). There 
is also evidence that female sex hormones are capable of modify-
ing decidual immune cells, such as DCs and uterine natural killer 
cells, from being actively pro-inflammatory to being tolerogenic 
(103). Considering that pregnancy outcomes essentially rely on 
the effective control of the inflammatory response, essential preg-
nancy hormones should be investigated in any study of immune 
cell changes during pregnancy.
Estrogen regulation of immune cells, whether innate or adap-
tive, has been established in recent years. Its presence can increase 
splenic neutrophil numbers, alter the phagocytic capacity of 
macrophages, and enhance the maturation of DCs (2). It has also 
been shown to regulate the activities of CD4+ and CD8+ T cells 
and promote the expansion and activity of Tregs by increasing 
FOXP3, PD-1, and cytotoxic T-lymphocyte-associated protein 4 
expression (34, 104, 105). RA and MS can both be ameliorated by 
estrogen-induced Treg expansion and activation which leads to 
immune suppression (104, 106). B cells are likewise affected by 
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the presence of estrogen. During lymphopoiesis, a rise in estrogen 
levels leads to a reduction of B cell precursors and an expansion of 
mature B cells. Estrogen activation therefore affects B cell matura-
tion, and ensures that the immune system is equipped to defend 
the body against pathogens if required (5).
Two receptors are responsible for estrogen-mediated signal-
ing—estrogen receptor α (ERα) and estrogen receptor β and upon 
activation act as transcription factors for a range of estrogen-sen-
sitive genes, with ERα more predominant on B cells (107). Studies 
of EAE demonstrate that the protective effect of 17β-estradiol 
(E2) comes from its interaction with ERα on immune cells, 
including B cells (106). While many studies have explored the 
protective effect of estrogen in autoimmune diseases, primarily 
by focusing on effects on Tregs (34, 108), others have highlighted 
the role of B cells by showing that E2 conferred protection against 
the induction of EAE in mice even after ablation of Treg; a result 
unsuccessful in B cell-deficient mice (6, 109). Specifically, E2 
augmented the frequency of splenic IL-10+ Bregs via the PD-1/
PD-L1 mechanism (110, 111) which led to a decline in the 
frequency of CD11b+CD45hi-activated macrophages, DCs, and 
infiltrating CD4+ cells in the spinal cord (112). Together, these 
results suggest that Bregs may have carried out this protective 
effect via their responsiveness to estrogen. This was confirmed 
by studies which demonstrated that estrogen-receptor positive B 
cells upregulate Treg function in EAE (34).
The effect of progesterone on innate immune cells, mainly 
monocytes, DCs, and natural killer cells, has also been eluci-
dated (103), and in a manner similar to estrogen, depends on 
the presence of progesterone receptors. These receptors also act 
as nuclear transcription factors upon activation and may either 
be progesterone receptor A (PR-A) or progesterone receptor B 
(PR-B) (113). The specific actions of progesterone relevant to 
myometrial function are mediated by the combined and distinct 
genomic actions of PR-A and PR-B. Myometrial cells express 
PR-B for most of the pregnancy, facilitating progesterone-medi-
ated Th2-like maternal immune responses, resulting in reduced 
production of pro-inflammatory cytokines, and increased secre-
tion of IL-10 (97, 114). At the latter part of pregnancy nearing 
the onset of parturition, PR-A gene expression becomes more 
predominant, blocking the transcriptional anti-inflammatory 
activity of PR-B and consequently increasing pro-inflammatory 
gene expression and promoting labor (97). Progesterone function 
in cancer and autoimmune diseases occurs comparably to that in 
pregnancy, in that progesterone inhibits T cell proliferation and 
pro-inflammatory cytokines IL-2, IL-17, and IFNγ expression 
while enhancing IL-4, IL-5, IL-6, and IL-10 cytokine produc-
tion (98, 115). Moreover, there is a concurrent expansion of B 
cells associated with the increase in IL-10, and a lack of effect of 
progesterone on Tregs (116). Collectively, this suggests a possible 
signaling pathway wherein progesterone elicits IL-10 augmenta-
tion by activating Bregs.
The molecular mechanisms by which estrogen and pro-
gesterone operate appear to be distinct from one another. 
Whereas estrogen elicits a strong effect on Tregs, progesterone 
does not. However, both have been documented to affect the B 
cell immune profile. The current literature gives insights as to 
how the female sex hormones shape the immune response in 
various clinical conditions, and overall indicate that estrogen 
and progesterone foster a tolerant environment within the 
pregnancy milieu by expanding all regulatory cells. Changes in 
the circulating amount and distribution of these cells during 
pregnancy indicates that adaptations are in place to ensure that 
the mother’s body is well equipped to conceive and grow a semi-
allogeneic fetus.
Bregs iN PReGNANCY
Previous studies of Bregs in the context of autoimmune disease, 
graft transplantation, and cancer all indicate one thing—Bregs 
dampen the inflammatory response and foster a stable tolerant 
immune profile within the local microenvironment. Based on 
the current literature, it is therefore reasonable to speculate that 
Bregs may be a key player in pregnancy. Their anti-inflammatory 
role in autoimmunity and graft tolerance suggest relevance to 
the induction of maternal immunological tolerance, while their 
pro-tumorigenic role in cancer may be applicable in pregnancy, 
i.e., maternal–fetal cognate interactions may hijack naïve B cells 
and educate them to become Bregs thus ensuring the fetus’ 
unperturbed growth. The pregnancy hormones estrogen and 
progesterone are likewise critically involved in the establishment, 
maintenance, and termination of pregnancy.
During pregnancy, as the mother’s womb houses and protects 
the semi-allogeneic fetus, the response of the maternal immune 
system is the key determinant to pregnancy success, with failure 
to induce selective immune tolerance toward the fetus resultant in 
pregnancy loss. Modification of the maternal immune response is 
orchestrated by multiple cytokines that influence the nature and 
abundance of leukocyte subsets in the uterus and placenta and 
includes the reduction of antigen-presenting function of mono-
cytes, macrophages, and DCs; inhibition of natural killer cells, T 
cells, and B cells; proliferation of uterine killer cells; maintenance 
of tolerogenic DCs; and the induction of Tregs (117). These 
immunological adaptations during early pregnancy pave the 
way for two main objectives—to protect the fetus from immune 
rejection and to facilitate the tissue remodeling processes needed 
for placental development (118).
Primarily, Bregs are considered highly relevant in the preg-
nancy milieu as they are a major cellular source of the potent 
anti-inflammatory cytokine IL-10. This cytokine is vital for opti-
mal pregnancy outcomes, with IL-10 deficiency associated with 
fetal resorption, growth restriction, and even death (118–120). 
IL-10 is found in abundant amounts in the uterus and placenta 
during pregnancy and has been identified as a critical player for 
counteracting the pro-inflammatory cytokine response. Even 
at the initial conception stage, inflammation resulting from the 
recognition of paternal antigens is thwarted by the presence of 
IL-10 (121). Furthermore, administration of a sub-clinical dose 
of LPS to pregnant IL-10−/− mice resulted in a 10-fold reduction 
in viability of semi-allogeneic fetuses compared to unaffected 
controls. Analysis of maternal serum and uterine tissue in these 
LPS challenged IL-10−/− mice demonstrated high levels of the 
pro-inflammatory cytokines TNFα, IL-6, IL-1A, and IL-12p40, 
a result which could be abrogated by administration of exog-
enous IL-10 (118, 122, 123). Therefore, IL-10 confers pregnancy 
FiGURe 1 | Schematic illustration of the hypothetical feedback loop between regulatory B cell (Breg), regulatory T cell (Treg), and dendritic cells 
(DCs) during pregnancy. Bregs create a tolerant pregnancy milieu either by direct induction and expansion of the Treg population via CD80/CD86 costimulation 
and/or IL-10 and TGFβ production (depicted in red); or by inhibition of DC maturation causing retention of a tolerogenic phenotype and in turn expansion of the Treg 
population via IL-10 (depicted in blue). Tregs and tolerogenic DCs produce IL-10 and may maintain the feedback loop responsible for negative regulation within the 
pregnancy milieu. The exact mechanism by which Bregs recruit Tregs and inhibit DC maturation in the pregnancy context is, however, yet to be established.
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protection by multiple mechanisms including inhibition of 
pro-inflammatory cells such as macrophages and monocytes, 
and suppression of pro-inflammatory cytokine and chemokine 
production such as TNFα, IL-6, IL-1a, IL-8, and IL-12 (118, 
124, 125). These findings demonstrate the capacity of IL-10 to 
regulate the inflammatory response in the uterus and placenta 
during gestation.
Evidence of a direct role for Bregs was indicated in compara-
tive mouse studies of normal and abortion-prone pregnancies 
which showed a diminished frequency of B10 cells in the mater-
nal spleen of abortion-prone mice, whereas normal pregnancies 
harbored an increased number of B10 cells. Furthermore, adop-
tive transfer of B10 cells rescued pregnancies in abortion-prone 
mice, by inhibition of DC maturation and expansion of the 
Treg population (126). Another Breg phenotype reported as 
critical to pregnancy success are the MZ B cells that are found 
expanded in the spleen of normal pregnant mice, but lacking 
in mice undergoing pregnancy complications. Additionally, 
successful pregnancy was correlated with the capacity of MZ B 
cells to produce enhanced levels of immunoglobulin (IgM and 
IgA) which likely shifts the immune response from a Th1-like 
to a Th2-like profile (127). Although also IL-10 competent (22), 
there is no evidence yet linking MZ B cell cytokine production to 
their role in pregnancy well-being. In humans, IL-10-producing 
CD19+CD24hiCD27+ B cells in the peripheral blood have been 
shown to be significantly higher in women undergoing normal 
pregnancies as opposed to non-pregnant women, or women 
who had suffered spontaneous abortions (128). Bregs isolated 
from peripheral blood of pregnant women taken during the first 
trimester successfully inhibited TNFα secretion by activated T 
effector cells ex vivo (128). Interestingly, CD24hiCD38hi Bregs 
were found to be significantly lower during the third trimester of 
pregnancy and on delivery day compared to non-pregnant and 
postpartum controls, possibly as a result of a drop in female sex 
hormones that influence B cell activation (129). Although limited 
in number, these studies on Breg function in pregnancy, and the 
underpinning Breg-mediated immunosuppression, parallels that 
observed in autoimmune disease, graft tolerance, and cancer. 
In all conditions, Bregs impose a suppressive environment via 
induction and maintenance of Tregs, modification of the Th 
response, and inhibition of effector cell responses including 
cytolytic T cells, NK cells, and DCs.
As Breg function in pregnancy appears to be interlinked 
with that of Treg and DCs, defining the working mechanisms is 
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requisite. Both Tregs and DCs are critical players in determin-
ing pregnancy outcomes. In normal pregnancy, the majority 
of decidual DCs remain immature which contributes to the 
maintenance of a fetal-tolerant local environment. These imma-
ture DCs are thus referred to as tolerogenic DCs (130). Tregs 
are likewise crucial contributors in achieving and maintaining 
maternal–fetal immune tolerance. In mice, a natural periodic 
accumulation of Tregs during the estrus stage is seen, purport-
edly in preparation for the implantation of a semi-allogeneic 
fetus (131). At the onset of embryo implantation, Tregs are 
recruited to the para-aortic lymph nodes draining the uterus 
(132). Expansion of the Treg population is critical in improving 
the rates of successful pregnancy as deficiency or harboring 
insufficient numbers of Tregs in the vicinity of the uterus at any 
time during pregnancy leads to abortion or miscarriage (4, 133). 
In the context of pregnancy, tolerogenic DCs and Tregs foster a 
fetal-tolerant environment via production of anti-inflammatory 
IL-10 and TGF-β (134).
During pregnancy, if an anti-inflammatory signal such as 
IL-10 or TGF-β is lacking, the DC phenotype remains such that it 
prevents the activation of T cells that protect the semi-allogeneic 
fetus (135). It is thus pertinent that DCs retain their immature 
state to acquire the tolerogenic phenotype. IL-10 and or TGF-β 
must then be initially present in the pregnancy milieu to either 
set off the induction of tolerogenic DCs followed by the induction 
of Tregs, or directly drive the induction of Tregs. However, given 
that Bregs are (1) established sources of both IL-10 and TGF-β, (2) 
significantly increased in numbers during normal pregnancy, and 
(3) are responsive to endocrine modulation, it is plausible that 
Bregs also play a critical role in pregnancy, especially in the initial 
induction of maternal immunological tolerance. In support, the 
findings of Jensen et al. (126) suggest that IL-10 production from 
B10 cells likely influences the non-maturation of IL-10-receptor 
rich DCs which then expand the Treg population in pregnant 
mice. Based on the current literature indicating similar immu-
nosuppressive roles and direct interface among these three types 
of immune cells, a Breg–Treg–tolerogenic DC feedback loop is 
proposed for the maintenance of a tolerant pregnancy milieu 
(illustrated in Figure 1).
CONCLUSiON
The function of Bregs in autoimmune diseases, graft tolerance, 
and cancer sheds light as to their emerging role in pregnancy. 
Studies of autoimmune disease and graft tolerance indicate that 
the immune response attempts to regain homeostasis by Breg-
mediated negative regulation. In cancer, tumor-educated Bregs 
represent an adaptation that encourages a mutated self to survive 
and proliferate. Integrating these fields, it is reasonable to suggest 
that pregnancy represents a predicament common to both—the 
need for constant immune tolerance for the duration of the 
pregnancy, and the permission to allow a semi-allogeneic fetus 
to grow within. However to date, the direct role that Bregs play in 
maternal tolerance in pregnancy has not been fully investigated, 
and is the subject of ongoing investigations in our laboratory. 
Supporting studies suggest that the pregnancy sex hormones, 
estrogen and progesterone, may also be critical prerequisites 
for Breg activation and function, with a Breg–Treg–tolerogenic 
DC feedback loop potentially underpinning the induction and 
maintenance of a tolerant environment necessary for a successful 
pregnancy. Bregs therefore, are potential guardians of pregnancy 
well-being, and require further exploration as to their role in this 
context.
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